Topical 2% Povidone-Iodine Gel in Verruca Vulgaris

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

90 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-02-12

Study Completion Date

2021-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a multi-center, randomized, double-blind, placebo-controlled phase 2 study in subjects 8 years of age and older who present with verruca vulgaris (common warts) and desire treatment. Subjects may have up to a total of 6 common warts located on their trunk or extremities that will be treated with study medication and followed throughout the study protocol therapy. All warts will be treated two times per day (BID) for12 weeks. Approximately 90 subjects will be enrolled in this study.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital Warts

NCT03981822

Condylomata Acuminata Papillomavirus Infections Skin Diseases, Viral +5 more

COMPLETED PHASE2

Cantharidin and Occlusion in Verruca Epithelium

NCT03487549

Common Wart Warts Hand Warts +9 more

COMPLETED PHASE2

ALC-919 For The Treatment Of Common Warts

NCT02483455

Verruca Vulgaris

COMPLETED PHASE2

The Purpose of This Study is to Determine Whether Topical Application of PEP005 is Safe for the Treatment of Common Wart(s)

NCT00546611

Warts

WITHDRAWN PHASE1

Safety and Efficacy of Varying Regimens of CANDIN for Treatment of Common Warts (Verruca Vulgaris)

NCT02393417

Warts

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Warts

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

VBP-245

Topical 2% Povidone-Iodine Gel

Group Type EXPERIMENTAL

VBP-245

Intervention Type DRUG

2% Povidone-Iodine Gel

Control

Placebo Gel (no Povidone-Iodine)

Group Type PLACEBO_COMPARATOR

Placebo Gel (no Povidone-Iodine)

Intervention Type DRUG

Placebo Gel (no Povidone-Iodine)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

VBP-245

2% Povidone-Iodine Gel

Intervention Type DRUG

Placebo Gel (no Povidone-Iodine)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subject is able to comprehend and is willing to sign an informed consent/assent for participation in this study.
* Male or female ≥ 8 years old.
* Subject has a clinical diagnosis of verruca vulgaris (common warts).
* Subject has up to 6 warts located on the trunk or extremities

Exclusion Criteria

* Subject has clinically atypical warts on the trunk or extremities.
* Subject is immunocompromised (e.g., due to chemotherapy, systemic steroids, genetic immunodeficiency, transplant status, etc.)
* Subject has periungual, subungual, genital, anal, mosaic, plantar, flat, or filiform wart identified as a wart for study treatment.

Minimum Eligible Age

8 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No